kaposi
sarcomaassoci
herpesviru
kshv
oncogen
herpesviru
associ
variou
aidsrel
malign
like
herpesvirus
multipl
process
requir
kshv
lytic
replic
includ
viral
transcript
viral
dna
synthesi
capsid
assembl
occur
virusinduc
intranuclear
structur
term
replic
transcript
compart
rtc
utilis
novel
methodolog
combin
subcellular
fraction
quantit
proteom
identifi
cellular
protein
recruit
kshvinduc
rtc
thu
play
key
role
kshv
lytic
replic
show
sever
isoform
chaperon
famili
redistribut
cytoplasm
nucleu
coincid
initi
format
kshvinduc
rtc
demonstr
nuclear
chaperon
foci
dynam
initi
form
adjac
newli
form
kshv
rtc
howev
later
time
point
chaperon
move
within
kshv
rtc
complet
colocalis
activ
replic
viral
dna
function
signific
isoform
recruit
kshv
rtc
also
examin
use
specif
isoform
small
molecul
inhibitor
intriguingli
result
highlight
essenti
role
isoform
kshv
replic
cycl
independ
protein
stabil
matur
notabl
inhibit
isoform
preclud
kshv
rtc
format
rna
polymeras
ii
rnapii
relocalis
viral
genom
lead
abolish
global
kshv
transcript
subsequ
viral
protein
synthesi
dna
replic
new
find
reveal
novel
mechan
regul
kshv
lytic
replic
highlight
potenti
inhibitor
novel
antivir
agent
molecular
chaperon
famili
import
role
cell
surviv
recent
evid
also
implic
function
varieti
diseas
includ
cancer
identifi
emerg
drug
target
kaposi
plo
pathogen
molecular
chaperon
repres
larg
group
protein
essenti
maintain
cellular
homeostasi
surviv
role
protein
numer
facilit
correct
protein
fold
unfold
assembl
disassembl
multimer
protein
complex
particip
transloc
protein
vesicl
organel
stabilis
wide
rang
signal
molecul
prevent
aggreg
nonn
protein
review
heat
shock
protein
hsp
classifi
accord
molecular
weight
sever
famili
small
hsp
less
kda
function
import
famili
molecular
chaperon
exemplifi
emerg
implic
varieti
diseas
includ
cancer
neurodegener
viral
infect
gain
signific
interest
recent
potenti
drug
target
eukaryot
multipl
gene
encod
chaperon
famili
amongst
conserv
protein
evolut
major
isoform
constitut
express
stressinduc
endoplasm
reticulum
resid
mitochondri
form
isoform
ntermin
domain
harbour
highli
conserv
atpas
ctermin
substrat
bind
domain
isoform
compris
induc
constitutivelyexpress
isoform
respect
er
resid
mitochondri
form
also
possess
ntermin
atp
bind
domain
although
similar
atpbind
domain
found
chaperon
famili
presenc
atpas
pocket
famili
chaperon
make
protein
desir
target
small
molecul
inhibitor
therapeut
potenti
compound
especi
evid
sever
inhibitor
alreadi
reach
phase
ii
iii
clinic
trial
target
isoform
challeng
recent
specif
inhibitor
also
undergon
clinic
trial
importantli
develop
highli
specif
inhibitor
isoform
may
potenti
treatment
divers
group
virus
function
import
isoform
life
cycl
numer
virus
highlight
past
year
distinct
isoform
usurp
aid
mani
stage
viral
replic
vari
viral
entri
uncoat
transcript
envelop
protein
matur
morphogenesi
dna
replic
therefor
import
chaperon
life
cycl
wide
rang
virus
suggest
potenti
protein
target
broadspectrum
antivir
kaposi
sarcomaassoci
herpesviru
kshv
caus
agent
sever
aidsassoci
malign
includ
kaposi
sarcoma
ks
highli
vascular
tumour
ne
purifi
complet
due
multipl
subcellular
connect
outer
nuclear
membran
continu
endoplasm
reticulum
interact
cytoskeleton
inner
nuclear
membran
bind
host
chromatin
thu
took
advantag
incomplet
puriti
could
isol
ne
embed
nuclear
pore
complex
also
compon
found
ne
neighbourhood
rtc
utilis
novel
approach
demonstr
cellular
chaperon
famili
significantli
increas
neassoci
rtc
reactiv
cell
function
dissect
demonstr
chaperon
specif
recruit
peripheri
incipi
rtc
coincid
time
format
activ
replic
viral
dna
synthesis
chaperon
recruit
within
rtc
strikingli
inhibit
isoform
preclud
rtc
format
curtail
chaperon
redistribut
within
rtc
rnapii
recruit
viral
promot
importantli
abrog
lytic
replic
occur
without
affect
cell
viabil
suggest
cellular
housekeep
function
carri
chaperon
compromis
inhibitor
may
provid
novel
therapeut
approach
treatment
kshvassoci
malign
particular
would
interest
determin
efficaci
combin
potenti
inhibit
lytic
replic
use
inhibitor
previou
report
effect
inhibitor
erad
latent
kshv
reservoir
cellular
chaperon
enhanc
neassoci
rtc
reactiv
cell
investig
differenti
proteom
chang
occur
kshv
lytic
replic
neassoci
rtc
utilis
cell
line
contain
latent
recombin
kshv
viru
cell
line
reactiv
full
lytic
replic
cycl
via
chemic
induct
unreactiv
cell
grown
isotop
label
media
cell
reactiv
grown
labelfre
media
isotop
label
complet
cell
reactiv
h
nuclear
envelop
ne
success
purifi
use
recent
describ
method
minor
modif
western
blot
analysi
ne
prepar
demonstr
enrich
nucleoporin
nup
lamin
histon
loss
cytoplasm
gapdh
nucleolar
protein
compar
whole
cell
wc
lysat
fig
essenti
kshv
mrna
process
protein
viral
rta
serv
marker
lytic
viral
replic
rtc
enrich
protein
known
recruit
kshv
rtc
monoclon
antibodi
recognis
phenylalanineglycin
fg
repeat
motif
present
numer
nup
polyclon
antibodi
lamin
use
assess
enrich
ne
region
ne
prepar
show
higher
number
nup
close
arrow
respect
wc
prepar
although
nup
lost
follow
salt
wash
open
arrow
follow
lcmsm
analysi
use
minimum
three
uniqu
peptid
assign
singl
protein
protein
remain
unchang
abund
irrespect
kshv
lytic
infect
five
protein
signific
reduct
ratio
cutoff
ne
reactiv
cell
contrast
protein
show
signific
increas
ratio
cutoff
lytic
replic
importantli
multipl
cellular
protein
known
expect
local
within
herpesviru
rtc
associ
kshv
orilyt
hcmv
transactiv
protein
herp
simplex
protein
found
significantli
increas
ne
region
reactiv
cell
use
less
stringent
ratio
cutoff
tabl
cellular
protein
includ
blm
topoisomeras
ii
dead
box
helicas
thu
lcmsm
result
confirm
correct
isol
ne
region
accompani
rtc
importantli
mani
identifi
protein
like
repres
novel
cellular
protein
hijack
kshv
due
subcellular
fraction
carri
also
uncommon
use
urea
protein
extract
lcm
ms
protein
identifi
lcmsm
seen
dataset
bioinformat
analysi
reveal
sever
upregul
pathway
ratio
cutoff
reactiv
cell
tabl
particular
interest
upregul
pathway
relat
protein
fold
includ
sever
isoform
associ
cochaperon
dnaj
famili
tabl
notabl
constitut
express
chaperon
present
increas
uniqu
peptid
assign
protein
highest
fold
increas
associ
uniqu
peptid
number
protein
identifi
lcmsm
could
due
increas
express
redistribut
cytoplasm
ne
region
kshv
lytic
replic
therefor
due
vital
import
isoform
replic
cycl
wide
rang
viral
famili
focuss
studi
herein
role
three
main
isoform
kshv
lytic
replic
redistribut
cytoplasm
peripheri
within
kshvinduc
rtc
verifi
enrich
neassoci
rtc
reactiv
cell
detect
quantit
proteom
approach
indirect
immunofluoresc
use
label
endogen
protein
trex
cell
kshv
latent
infect
blymphocyt
cell
line
contain
myctag
version
viral
rta
control
doxycyclineinduc
promot
protein
equal
distribut
cytoplasm
nucleu
unreactiv
cell
fine
punctuat
pattern
fig
similar
local
seen
earli
lytic
replic
h
reactiv
rta
protein
diffus
nucleu
success
enrich
nuclear
envelop
region
associ
kshv
rtc
cell
success
enrich
ne
region
unreactiv
reactiv
h
cell
demonstr
western
blot
equal
amount
total
protein
extract
whole
cell
wc
nuclear
envelop
ne
fraction
use
monoclon
antibodi
specif
recognis
phenylalanineglycin
fg
repeat
motif
present
numer
nucleoporin
nup
close
arrow
point
nup
detect
ne
enrich
open
arrow
point
nucleoporin
lost
ne
enrich
sever
fg
nup
togeth
histon
lamin
markedli
enrich
ne
fraction
compar
wc
fraction
nucleolar
protein
cytoplasm
gapdh
protein
decreas
ne
fraction
indic
correct
subcellular
fraction
viral
rtcassoci
rta
protein
use
monitor
lytic
reactiv
assess
rtc
enrich
antibodi
detect
full
length
protein
prior
rtc
format
fig
contrast
later
reactiv
time
point
h
rta
organis
small
viral
rtc
peripher
locat
nucleu
numer
nuclear
foci
predominantli
adjac
rtc
observ
fig
late
reactiv
time
point
h
cellular
chromatin
marginalis
nuclear
peripheri
fig
nucleu
highlight
yellow
larger
foci
avidli
accumul
within
fullydevelop
rtc
fig
reduc
level
cytoplasm
also
observ
time
point
fig
arrow
suggest
redistribut
cytoplasm
nucleu
kshv
lytic
replic
support
fact
fraction
trex
cell
nuclear
n
cytoplasm
c
fraction
display
enrich
nuclei
reactiv
cell
occur
without
notic
increas
protein
level
whole
cell
wc
lysat
fig
due
observ
redistribut
kshv
rtc
coloc
studi
site
viral
dna
replic
perform
trex
cell
cell
triplelabel
clickit
edu
alexa
fluor
antibodi
specif
rta
unreactiv
cell
newli
synthes
cellular
dna
midsphas
edu
incorpor
occur
mainli
nuclear
peripheri
previous
observ
cell
type
fig
earli
reactiv
adjac
rta
present
small
viral
rtc
contain
activ
replic
viral
dna
fig
arrow
stage
proport
also
colocalis
rta
fig
late
reactiv
cellular
chromatin
marginalis
much
larger
rtc
visibl
newli
synthes
cellular
dna
appar
complet
colocalis
newli
synthes
viral
dna
rta
fig
locat
two
main
isoform
kshv
lytic
replic
also
investig
indirect
immunofluoresc
microscopi
cytoplasm
unreactiv
trex
cell
fig
contrast
increas
nuclear
label
observ
reactiv
cell
display
similar
chaperon
foci
seen
earli
reactiv
fig
occasion
cell
display
rtc
complet
fill
fig
asterisk
larg
foci
posit
adjac
rtc
also
seen
reactiv
cell
later
time
point
fig
arrow
colocalis
activ
replic
viral
dna
also
observ
late
reactiv
fig
nuclear
foci
appear
time
kshv
rtc
assembl
suggest
chaperon
could
involv
rtc
assembl
addit
complet
coloc
viral
dna
indic
chaperon
could
also
particip
viral
dna
replic
andor
capsid
assembl
contrast
endoplasm
reticulum
er
isoform
redistribut
reactiv
trex
cell
fig
consist
er
retent
signal
nevertheless
reactiv
cell
seem
accumul
larger
amount
er
confirm
result
immunoflouresc
studi
also
perform
use
prior
rtc
format
rta
diffus
nucleu
ii
h
reactiv
viral
rta
assembl
incipi
rtc
detect
cytoplasm
instead
numer
nuclear
foci
posit
predominantli
adjac
rtc
seen
iii
later
reactiv
time
larg
foci
complet
recruit
within
rtc
cytoplasm
deplet
indic
iv
arrow
nucleu
highlight
yellow
show
typic
kshv
fulli
developedrtc
cellular
chromatin
marginalis
nuclear
peripheri
b
unreactiv
reactiv
h
trex
cell
fraction
whole
cell
wc
cytoplasm
c
nuclear
n
fraction
equal
amount
total
protein
fraction
analys
western
blot
nuclear
fraction
characteris
enrich
lamin
absenc
cytoplasm
gapdh
cytoplasm
fraction
show
invers
profil
small
decreas
cytoplasm
correl
small
increas
nuclear
detect
reactiv
cell
support
redistribut
cytoplasm
nucleu
c
trex
cell
remain
unreactiv
reactiv
h
iiiii
follow
triplelabel
antibodi
specif
rta
clickit
edu
alexa
fluor
latter
allow
visual
newli
synthes
dna
earli
reactiv
proport
protein
adjac
small
viral
rtc
arrow
point
small
kshv
rtc
fill
viral
dna
ii
also
partial
colocalis
viral
dna
ii
rta
ii
small
rtc
later
reactiv
time
complet
move
within
fullydevelop
rtc
strongli
colocalis
viral
dna
iii
rta
iii
cell
presenc
recombin
viru
track
express
green
fluoresc
protein
gfp
promot
lytic
reactiv
level
monitor
express
red
fluoresc
protein
rfp
kshv
lytic
noncod
polyadenyl
nuclear
pan
rna
promot
unreactiv
cell
display
cytoplasm
label
reactiv
cell
h
reactiv
reveal
nuclear
accumul
appear
assembl
within
small
rtc
fig
arrow
fig
arrow
respect
incomplet
redistribut
foci
rtc
like
due
asynchron
progress
lytic
cycl
induc
cell
tpa
sodium
nbutyr
doxycyclineinduc
trex
cell
similarli
trex
cell
redistribut
cell
although
larger
amount
appear
accumul
er
reactiv
cell
fig
agreement
significantli
increas
amount
detect
ne
region
cell
tabl
result
clearli
demonstr
kshv
specif
redistribut
molecular
chaperon
cytoplasm
nucleu
contrast
coincid
initi
format
kshv
rtc
treatment
small
molecul
inhibitor
abrog
viral
protein
synthesi
noncytotox
concentr
member
chaperon
famili
possess
ntermin
nucleotid
bind
domain
atpas
activ
essenti
function
examin
implic
redistribut
kshv
rtc
small
molecul
inhibitor
analog
utilis
inhibitor
demonstr
specif
target
highli
homolog
atpas
pocket
present
three
main
human
isoform
highli
diverg
structur
atpas
pocket
found
chaperon
famili
function
atp
mimet
specif
inhibit
atpas
activ
member
famili
initi
cytotox
compound
assess
unreactiv
trex
cell
follow
h
inhibitor
exposur
use
nonradioact
mt
assay
quantit
assess
cell
prolifer
drastic
reduct
cell
metabol
activ
seen
inhibitor
concentr
higher
fig
thu
concentr
rang
use
cytotox
character
fig
inhibitor
trigger
apoptosi
dosedepend
manner
demonstr
caspas
cleavag
full
length
poli
adpribos
polymeras
protein
cleav
fig
small
amount
seen
signific
increas
form
result
confirm
apotoxglo
triplex
assay
quantit
measur
viabil
cytotox
activ
effector
sampl
well
h
inhibitor
treatment
dosedepend
decreas
viabil
evid
cytotox
activ
consider
increas
concentr
higher
fig
next
trex
cell
reactiv
h
presenc
drug
vehicl
dmso
rang
increas
inhibitor
concentr
cell
treat
inhibitor
noncytotox
concentr
reveal
drastic
reduct
level
earli
late
minor
capsid
mcapsid
protein
moder
reduct
immediateearli
rta
protein
also
seen
fig
note
detect
fusion
protein
rtamyc
express
kshv
genom
antimyc
antibodi
decreas
rtamyc
dramat
seen
viral
rta
suggest
decreas
viral
protein
due
gener
cytotox
effect
inhibitor
cell
viral
cellular
protein
specif
affect
addit
cellular
control
protein
level
larg
subunit
rnapii
halflif
h
assess
antibodi
specif
differ
phosphoryl
form
rnapii
protein
level
form
significantli
chang
presenc
inhibitor
protein
importantli
presenc
level
upregul
upregul
univers
hallmark
inhibit
vitro
also
clinic
trial
point
select
isoform
chaperon
machineri
report
crucial
stabil
andor
matur
multipl
viral
protein
therefor
ascertain
whether
isoform
could
stabilis
essenti
kshv
lytic
protein
rta
trex
cell
reactiv
h
allow
suffici
viral
protein
express
follow
addit
dmso
control
conjunct
cycloheximid
chx
block
de
novo
protein
synthesi
protein
lysat
collect
differ
time
addit
chx
halflif
rta
protein
inhibitortr
cell
alter
compar
dmsotreat
cell
fig
result
indic
observ
decreas
viral
protein
synthesi
prior
translat
neither
viral
rta
protein
client
protein
isoform
highlight
potenti
novel
role
isoform
kshv
replic
cycl
independ
viral
protein
stabil
matur
corrobor
result
experi
also
repeat
cell
cell
metabol
activ
cleavag
viabil
cytotox
activ
unreactiv
cell
assess
rang
increas
inhibitor
concentr
fig
occas
inhibitor
trigger
apoptosi
fig
caus
pronounc
cell
cycl
arrest
h
exposur
concentr
demonstr
reduc
number
metabol
activ
cell
exhibit
increas
cytotox
fig
known
apoptot
potenti
cell
linedepend
caus
cell
cycl
arrest
human
colon
breast
lung
tumour
cell
line
cell
also
reactiv
h
presenc
drug
vehicl
dmso
increas
inhibitor
concentr
endogen
rta
mcapsid
protein
level
moder
reduc
cell
treat
inhibitor
concentr
sever
reduc
cellular
protein
remain
unaffect
fig
rel
high
inhibitor
concentr
compar
trex
cell
nonetheless
concentr
shown
necessari
inhibit
isoform
human
carcinoma
cell
line
previous
seen
trex
cell
block
de
novo
protein
synthesi
chx
cell
halflif
rta
protein
reduc
even
presenc
fig
support
find
seen
trex
cell
suggest
decreas
viral
protein
product
due
pretransl
event
use
mt
assay
ii
dosedepend
cleavag
full
length
fl
protein
cleav
cl
observ
presenc
b
unreactiv
cell
expos
h
increas
inhibitor
concentr
concentr
higher
result
increas
cytotox
activ
effector
demonstr
quantif
apotoxglo
triplex
assay
c
immunoblot
analysi
show
reactiv
cell
treat
noncytotox
inhibitor
concentr
h
reveal
decreas
viral
protein
compar
dmsotreat
sampl
cellular
protein
remain
unaffect
rnapiio
denot
hypophosphoryl
rnapii
rnapii
denot
serin
serin
rnapii
form
respect
cell
reactiv
h
allow
robust
viral
protein
product
dmso
control
ad
conjunct
cycloheximid
chx
block
de
novo
protein
synthesi
protein
lysat
collect
sever
time
postchx
addit
h
analys
western
blot
alter
halflif
rta
protein
thu
protein
client
isoform
small
molecul
inhibitor
caus
signific
reduct
viral
transcript
viral
dna
progeni
noncytotox
concentr
block
kshv
protein
synthesi
occur
pretransl
viral
gene
express
quantifi
absenc
presenc
trex
cell
reactiv
h
twostep
quantit
revers
transcript
pcr
qrtpcr
carri
quantifi
rang
viral
transcript
signific
decreas
earli
pan
vgpcr
late
gl
gb
viral
transcript
orilyt
transcript
observ
dosedepend
manner
transcript
except
vgpcr
significantli
reduc
inhibitor
concentr
fig
determin
whether
cellular
transcript
neg
affect
presenc
firstli
stabil
gapdh
transcript
determin
mrna
decay
assay
use
transcript
inhibitor
actinomycin
acd
trex
cell
h
acd
treatment
amount
gapdh
mrna
reduc
half
fig
indic
short
stabil
gapdh
mrna
cell
line
plot
raw
cycl
threshold
c
gapdh
transcript
sampl
viral
transcript
quantifi
h
treatment
amount
total
rna
convert
cdna
sampl
cellular
transcript
compromis
similar
c
expect
sampl
inde
sampl
treat
within
c
c
dmsotreat
sampl
concentr
higher
gapdh
mrna
level
significantli
reduc
compar
dmsotreat
sampl
shown
significantli
higher
c
valu
fig
consist
cytotox
profil
trex
cell
fig
clear
decreas
rtamyc
protein
express
kshv
genom
inhibitor
concentr
higher
fig
taken
togeth
result
suggest
cellular
transcript
compromis
concentr
higher
concentr
lower
transcript
occur
normal
interestingli
transcript
viral
gene
also
requir
host
rnapii
express
neg
affect
even
concentr
lower
next
assess
whether
inhibitor
also
caus
reduct
viral
dna
replic
trex
cell
reactiv
h
total
dna
isol
realtim
qpcr
perform
use
primer
specif
dmsotreat
cell
increas
viral
dna
load
inhibitor
concentr
higher
result
signific
reduct
viral
dna
fig
moreov
product
infecti
kshv
virion
trex
cell
evalu
presenc
vehicl
drug
dmso
cell
reactiv
treat
h
cultur
medium
centrifug
incub
h
cell
total
rna
isol
qrtpcr
carri
signific
reduct
releas
infecti
viral
progeni
observ
inhibitortr
cell
fig
viral
transcript
also
quantifi
h
reactiv
cell
absenc
presenc
noncytotox
concentr
drastic
decreas
observ
faintli
b
unreactiv
cell
expos
h
increas
inhibitor
concentr
reduc
number
metabol
activ
cell
accompani
increas
cytotox
observ
presenc
inhibitor
activ
effector
caspas
even
presenc
phenotyp
consist
cell
cycl
arrest
result
quantifi
apotoxglo
triplex
assay
c
immunoblot
analysi
show
reactiv
cell
treat
h
result
abrog
viral
protein
compar
dmsotreat
sampl
cellular
protein
remain
constant
cell
reactiv
h
allow
robust
viral
protein
express
dmso
control
ad
conjunct
cycloheximid
chx
block
de
novo
protein
synthesi
protein
lysat
collect
sever
time
postchx
addit
h
western
blot
perform
previous
seen
trex
cell
alter
halflif
rta
protein
isoform
essenti
kshv
lytic
replic
fig
intrigu
mrna
level
show
clear
doserespons
inhibitor
seen
mrna
trex
cell
howev
level
decreas
compar
dmsocontrol
cell
transcript
viral
transcript
test
cell
line
show
doserespons
howev
western
blot
reveal
complet
reduct
protein
cell
treat
fig
suggest
isoform
may
also
play
role
fold
protein
fact
previous
report
associ
least
newli
synthes
protein
biogenesi
thu
role
isoform
fold
viral
protein
rule
order
evalu
cellular
transcript
activ
presenc
first
determin
gapdh
transcript
stabil
mrna
decay
assay
use
acd
cell
contrast
trex
cell
gapdh
transcript
stabl
signific
reduct
level
h
acd
treatment
fig
halfliv
two
cellular
transcript
srag
cellular
mrna
export
adapt
histon
also
determin
cell
srag
transcript
reduc
follow
h
acd
treatment
fig
mrna
unstabl
nearli
reduct
h
acd
treatment
fig
plot
raw
c
valu
gapdh
transcript
sampl
viral
transcript
quantifi
h
treatment
significantli
chang
presenc
fig
next
unstabl
srag
mrna
measur
sampl
viral
transcript
quantifi
h
treatment
contrast
viral
transcript
cellular
transcript
significantli
reduc
indic
transcript
cellular
gene
occur
normal
even
presenc
high
concentr
fig
taken
togeth
result
demonstr
inhibit
isoform
function
abrog
express
viral
gene
variou
tempor
class
howev
cellular
rnapiimedi
transcript
compromis
use
noncytotox
concentr
follow
quantif
viral
transcript
cell
line
appear
reduct
seen
viral
gene
express
protein
product
infecti
virion
product
could
consequ
signific
global
reduct
viral
transcript
inhibitortr
cell
led
possibl
isoform
could
implic
activ
viral
promot
subsequ
transcript
altern
isoform
requir
kshv
rtc
format
viral
rta
coloc
trex
cell
rta
orang
colour
late
red
colour
orilyt
viral
transcript
significantli
reduc
compar
level
found
dmsotreat
sampl
sampl
normalis
gapdh
result
show
mean
three
biolog
replic
error
bar
standard
deviat
b
stabil
gapdh
transcript
assess
unreactiv
trex
cell
presenc
transcript
inhibitor
actinomycin
acd
control
dmso
cell
collect
time
point
indic
total
rna
extract
follow
qrtpcr
h
acd
treatment
amount
gapdh
transcript
reduc
half
c
compar
dmsotreat
cell
c
reduct
observ
h
treatment
c
averag
two
biolog
replic
error
bar
standard
deviat
shown
c
amount
gapdh
transcript
significantli
decreas
use
h
concentr
lower
compar
dmsotreat
sampl
contrast
concentr
higher
significantli
show
c
lower
dmso
sampl
indic
compromis
cellular
transcript
inhibitor
concentr
sampl
viral
transcript
quantifi
use
plot
c
valu
result
show
mean
three
biolog
replic
error
bar
standard
deviat
cell
reactiv
h
total
dna
isol
realtim
qpcr
perform
viral
dna
load
significantli
decreas
result
show
mean
three
biolog
replic
error
bar
standard
deviat
e
trex
cell
reactiv
h
presenc
vehicl
drug
dmso
cultur
medium
incub
h
cell
follow
total
rna
extract
qrtpcr
signific
decreas
viral
progeni
seen
inhibitortr
cell
result
show
mean
three
biolog
replic
error
bar
standard
deviat
master
latentlyt
transactiv
multipl
kshv
immediateearli
delayedearli
late
promot
investig
possibl
requir
rtamedi
transactiv
initi
assess
whether
interact
occur
rta
absenc
viral
protein
dna
cell
transient
transfect
h
control
pegfp
prtaegfp
immunoprecipit
carri
use
gfpspecif
antibodi
rtaegfp
precipit
endogen
contrast
control
egfp
protein
fig
addit
cell
transfect
control
pegfp
prtaegfp
h
examin
immunofluoresc
cell
express
egfp
protein
endogen
remain
cytoplasm
fig
egfprtaexpress
cell
strongli
colocalis
rta
nuclei
suggest
rta
express
alon
suffici
redistribut
nucleu
fig
similar
nuclear
redistribut
also
seen
endogen
fig
next
determin
whether
abl
disrupt
interact
egfprta
cell
cell
exhibit
similar
cytotox
profil
seen
cell
fig
cell
transient
transfect
prtaegfp
control
pegfp
allow
maxim
protein
express
avoid
interfer
inhibitor
transfect
inhibitor
ad
h
posttransfect
incub
h
prior
immunoprecipit
perform
western
blot
analysi
reveal
inhibitor
disrupt
interact
rta
even
high
inhibitor
concentr
fig
suggest
atpas
function
requir
interact
rta
protein
therefor
investig
whether
requir
rtamedi
transactiv
rtarespons
promot
dualluciferas
report
assay
system
utilis
cell
cotransfect
prtaegfp
along
renilla
luciferas
vector
either
promot
firefli
luciferas
report
vector
empti
report
vector
cotransfect
perform
use
pegfp
neg
control
h
posttransfect
cell
expos
h
increas
concentr
luciferas
activ
measur
longer
exposur
time
inhibitor
affect
format
control
renilla
luciferas
protein
halflif
h
suggest
isoform
may
requir
foldingmatur
enzym
presenc
egfprta
promot
report
construct
promot
activ
empti
vector
increas
howev
promot
activ
significantli
decreas
presenc
fig
confirm
result
cell
also
transient
cotransfect
ppanwt
plasmid
encod
genom
region
wild
type
pan
rna
includ
promot
region
either
prtaegfp
control
pegfp
h
posttransfect
either
vehicl
drug
dmso
ad
incub
h
follow
qrtpcr
quantif
rtpcr
immediateearli
blue
colour
earli
orang
colour
late
red
colour
orilyt
viral
transcript
show
transcript
significantli
decreas
compar
level
found
dmsotreat
sampl
sampl
normalis
gapdh
result
show
mean
three
biolog
replic
error
bar
standard
deviat
bd
stabil
cellular
gapdh
srag
transcript
determin
mrna
decay
assay
use
actinomycin
acd
control
dmso
cell
cell
collect
time
point
indic
total
rna
extract
follow
qrtpcr
averag
two
biolog
replic
error
bar
standard
deviat
shown
b
gapdh
transcript
stabl
signific
reduct
level
h
acd
treatment
c
h
acd
treatment
srag
mrna
level
reduc
show
rel
short
stabil
mrna
level
unstabl
nearli
reduct
h
acd
treatment
e
gapdh
transcript
level
remain
unchang
follow
h
treatment
reactiv
cell
sampl
viral
transcript
quantifi
use
plot
c
valu
f
unstabl
cellular
srag
mrna
significantli
decreas
presenc
treatment
compar
dmso
treatment
h
indic
cellular
transcript
compromis
even
high
concentr
sampl
viral
transcript
quantifi
use
quantifi
srag
sampl
normalis
gapdh
howev
signific
decreas
amount
pan
rna
seen
inhibitortr
cell
fig
indic
rtamedi
promot
transactiv
subsequ
synthesi
pan
rna
occur
normal
presenc
data
demonstr
isoform
directli
enhanc
rtamedi
transactiv
assess
transcript
activ
cellular
rnapii
presenc
inhibitor
halflif
pan
rna
determin
cell
cotransfect
ppanwt
prtaegfp
follow
h
posttransfect
acd
dmso
control
ad
h
transcript
inhibit
pan
rna
level
reduc
compar
dmsotreat
cell
fig
quick
reduct
stabil
pan
rna
absenc
protein
agreement
previou
report
thu
block
gener
rnapii
transcript
signific
reduct
pan
rna
level
observ
h
inhibitor
treatment
howev
pan
rna
level
reduc
cell
treat
h
fig
dramat
reduct
earli
late
orilyt
transcript
h
treatment
evid
kshv
infect
cell
line
use
howev
isoform
requir
rtamedi
transactiv
kshv
promot
transient
transfect
cell
thu
next
monitor
kshv
rtc
format
absenc
presenc
inhibitor
kshv
lytic
infect
trex
cell
reactiv
treat
either
control
dmso
inhibitor
h
reactiv
cell
fix
immunofluoresc
perform
use
rtaand
antibodi
dmsotreat
cell
display
abund
rtc
numer
nuclear
foci
partial
colocalis
rtc
cytoplasm
deplet
also
observ
fig
contrast
inhibitortr
cell
show
diffus
nuclear
rta
abl
assembl
rtc
fig
cell
nuclear
foci
still
visibl
much
less
numer
smaller
compar
foci
seen
dmsotreat
cell
significantli
follow
treatment
observ
cytoplasm
reactiv
cell
fig
subcellular
local
also
analys
dmsoand
inhibitortr
cell
confoc
profil
profil
perform
draw
line
long
enough
cover
nucleu
cytoplasm
either
side
nucleu
pixel
intens
data
point
equal
greater
data
point
previou
subsequ
pixel
background
nois
consid
peak
repres
foci
analys
immunofluoresc
endogen
cytoplasm
cell
express
egfp
contrast
strongli
colocalis
egfprta
nucleu
nucleoli
ii
c
cell
transient
transfect
control
pegfp
prtaegfp
h
posttransfect
ad
incub
h
immunoprecipit
carri
use
gfpspecif
antibodi
even
presenc
interact
egfprta
disrupt
cell
cotransfect
prtaegfp
along
renilla
luciferas
vector
either
promot
firefli
luciferas
report
vector
empti
report
vector
cotransfect
perform
use
pegfp
neg
control
protein
h
posttransfect
cell
expos
h
luciferas
activ
measur
compar
activ
rtarespons
promot
seen
dmsotreat
cell
occur
cell
treat
result
three
independ
transfect
averag
error
bar
standard
deviat
e
cell
transient
cotransfect
ppanwt
either
prtaegfp
control
pegfp
h
posttransfect
either
vehicl
drug
dmso
ad
incub
h
total
rna
extract
qrtpcr
perform
rtamedi
promot
transactiv
subsequ
synthesi
pan
rna
occur
similar
rate
presenc
control
dmso
result
three
independ
transfect
averag
error
bar
standard
deviat
f
stabil
pan
rna
determin
cell
cotransfect
ppanwt
prtaegfp
follow
h
posttransfect
actinomycin
acd
dmso
control
ad
cell
collect
time
point
indic
total
rna
extract
follow
qrtpcr
averag
two
biolog
replic
error
bar
standard
deviat
shown
isoform
essenti
kshv
lytic
replic
dmsotreat
cell
predominantli
show
peak
within
dapi
boundari
within
nucleu
fig
inhibitortr
cell
display
peak
outsid
dapi
boundari
cytoplasm
fig
asterisk
often
control
cell
signific
increas
cytoplasm
peak
seen
inhibitortr
cell
compar
dmso
control
cell
fig
fraction
reactiv
trex
cell
presenc
absenc
also
point
slightli
higher
level
cytoplasm
decreas
nuclear
inhibitortr
cell
compar
dmso
control
cell
fig
cell
also
label
clickit
edu
alexa
fluor
antibodi
specif
fig
percentag
assembl
rtc
dmsoand
inhibitortr
cell
also
calcul
dmsotreat
cell
present
assembl
rtc
inhibitortr
cell
show
assembl
rtc
fig
demonstr
chaperon
recruit
nucleu
essenti
assembl
kshv
rtc
treatment
suffici
impair
nuclear
chaperon
recruit
kshv
rtc
format
subcellular
localis
rnapii
also
assess
indirect
immunoflouresc
label
trex
cell
monoclon
antibodi
specif
recognis
unphosphoryl
phosphoryl
rnapii
unreactiv
cell
rnapii
exhibit
nuclear
local
exclud
nucleolu
fig
arrow
irrespect
presenc
dmso
fig
inhibitor
fig
howev
reactiv
dmsotreat
cell
rnapii
clearli
hijack
rtc
fig
contrast
reactiv
cell
treat
inhibitor
rnapii
diffus
throughout
nucleu
exclud
nucleoli
form
small
foci
fig
arrow
multipl
kshv
rtc
identifi
rtalabel
form
dmsotreat
cell
larg
numer
foci
recruit
cell
deplet
cytoplasm
confoc
imag
subject
profil
analysi
use
zeiss
zen
softwar
profil
conduct
cell
two
repres
confoc
imag
taken
object
includ
profil
total
dmsotreat
cell
repres
line
profil
yellow
line
accompani
rel
intens
channel
everi
pixel
along
line
shown
dmsotreat
reactiv
cell
dapi
intens
profil
show
valu
outsid
nucleu
boundari
rta
profil
show
peak
intens
lie
within
dapi
boundari
correspond
kshv
replic
compart
peak
lie
within
dapi
boundari
demonstr
nuclear
locat
intens
peak
close
resembl
rta
intens
peak
arrow
indic
coloc
rta
sinc
peak
occur
posit
along
line
b
cell
reactiv
treat
h
rta
diffus
nucleu
assembl
kshv
rtc
addit
nuclear
foci
smaller
less
abund
dmsotreat
cell
deplet
cytoplasm
b
confoc
profil
perform
cell
two
repres
confoc
imag
taken
object
total
inhibitortr
cell
analys
repres
line
profil
yellow
line
shown
inhibitortr
cell
peak
seen
outsid
dapi
boundari
correspond
cytoplasm
peak
asterisk
c
total
peak
total
nuclear
peak
per
cell
combin
confoc
imag
experiment
condit
data
convert
percentag
nuclear
cytoplasm
peak
cell
exhibit
small
rnapii
foci
diffus
nuclear
edu
label
fig
confirm
inhibit
isoform
function
abl
abolish
rnapii
recruit
viral
genom
also
utilis
chromatin
immunoprecipit
chip
assay
trex
polyclon
antibodi
rta
monoclon
antibodi
rnapii
use
immunoflouresc
analysi
rnapii
protein
nuclear
exclud
nucleoli
arrow
regardless
inhibitor
treatment
b
trex
cell
reactiv
treat
either
control
dmso
h
dmsotreat
cell
rnapii
rta
recruit
viral
rtc
arrow
inhibitortr
cell
rta
diffus
nucleu
rnapii
form
numer
small
foci
exclud
nucleoli
resembl
prerepl
site
ii
arrow
c
trex
cell
either
reactiv
r
presenc
dmso
h
unreactiv
u
cell
treat
dmso
use
assess
level
lytic
reactiv
chip
assay
carri
either
monoclon
rnapii
antibodi
mous
control
antibodi
igg
presenc
significantli
reduc
amount
rnapii
bound
viral
promot
detect
averag
three
independ
experi
shown
error
bar
standard
deviat
cell
either
reactiv
h
presenc
dmso
fig
unreactiv
control
cell
clear
enrich
rnapii
promot
gapdh
gene
rnapii
occup
viral
promot
minim
howev
kshv
reactiv
dmsotreat
cell
led
drastic
reduct
rnapii
promot
gapdh
signific
increas
rnapii
viral
promot
agreement
previou
immunofluoresc
result
show
rnapii
recruit
rtc
fig
convers
upon
treatment
inhibitor
amount
rnapii
bound
promot
orilyt
decreas
respect
compar
dmsotreat
reactiv
cell
importantli
result
indic
first
time
inhibit
isoform
lead
sever
impair
rnapii
recruit
multipl
viral
promot
includ
orilyt
confirm
essenti
role
format
kshv
rtc
specif
individu
sirnamedi
deplet
isoform
perform
cell
follow
four
day
postsirna
transfect
cell
reactiv
h
rna
protein
extract
sampl
deplet
evalu
western
blot
qrtpcr
latter
mrna
knockdown
fig
contrast
mrna
level
affect
confirm
specif
sirna
despit
success
knockdown
mrna
level
signific
amount
protein
remain
cell
fig
howev
even
modest
amount
deplet
protein
level
viral
transcript
except
pan
display
signific
reduct
sirnatr
sampl
compar
scrambl
sirnatr
cell
demonstr
qrtpcr
analysi
fig
gl
mrna
level
decreas
follow
knockdown
orilyt
rta
transcript
reduc
gb
level
suggest
deplet
impair
express
viral
gene
variou
tempor
class
thu
may
necessari
kshv
rtc
format
viral
dna
replic
also
assess
follow
knockdown
four
day
postsirna
transfect
cell
reactiv
h
signific
differ
scrambl
deplet
cell
fig
product
infecti
kshv
virion
also
evalu
h
reactiv
signific
differ
seen
scrambl
deplet
cell
fig
howev
result
surpris
due
incomplet
deplet
even
seven
day
posttransfect
fig
highlight
remark
stabil
protein
cell
line
suggest
deplet
enough
caus
reduct
viral
transcript
enough
caus
reduct
amount
viral
protein
thu
kshv
lytic
replic
remain
unaffect
also
possibl
abl
function
compens
next
specif
deplet
perform
cell
deplet
mrna
level
knockdown
fig
correl
effici
deplet
protein
level
fig
howev
cell
major
viral
gene
express
unaffect
apart
gl
pan
transcript
decreas
respect
fig
importantli
taken
togeth
result
indic
partial
deplet
protein
level
suffici
caus
reduct
viral
transcript
suggest
essenti
role
chaperon
format
kshv
rtc
wherea
may
subtl
effect
viral
gene
express
support
essenti
role
kshv
rtc
format
specif
silenc
trex
cell
nucleofect
carri
transfect
effici
monitor
cotransfect
sirna
togeth
pmaxgfp
encod
maxgfp
green
fluoresc
protein
copepod
pontellina
p
fig
note
higher
transfect
effici
expect
sirna
due
smaller
size
compar
plasmid
dna
four
day
postnucleofect
mrna
level
knockdown
fig
minor
deplet
protein
level
fig
due
stabil
protein
cell
incub
six
day
postnucleofect
follow
h
reactiv
immunofluoresc
rta
carri
rtc
format
dramat
decreas
nucleofect
similar
impair
kshv
lytic
replic
previous
report
electropor
trex
cell
nevertheless
scrambl
sirnatr
cell
group
cell
could
still
seen
display
rtc
reloc
fig
contrast
sirnatr
cell
fewer
rtc
visibl
exhibit
nuclear
fig
yellow
arrow
cell
fulli
deplet
identifi
lack
form
rtc
fig
white
arrow
result
strongli
suggest
essenti
chaperon
format
kshv
rtc
trex
cell
current
quantit
proteom
approach
becom
invalu
tool
largescal
highthroughput
identif
protein
complex
biolog
sampl
moreov
advanc
subcellular
fraction
offer
way
reduc
complex
sampl
analys
lcmsm
allow
identif
low
abund
protein
present
studi
develop
novel
quantit
proteom
approach
enhanc
subcellular
fraction
enabl
us
elucid
cellular
protein
composit
kshv
rtc
novel
approach
led
identif
sever
upregul
pathway
reactiv
cell
associ
ne
fraction
tabl
first
score
pathway
rna
posttranscript
modif
second
highlight
pathway
protein
synthesi
differ
ribosom
protein
identifi
third
score
pathway
dna
replic
recombin
repair
addit
isol
ne
region
unreactiv
reactiv
cell
follow
uncommon
use
urea
protein
extract
led
mass
spectrometr
identif
sever
isoform
respect
cochaperon
signific
level
neassoci
rtc
reactiv
cell
immunoflouresc
analysi
confirm
endogen
redistribut
cytoplasm
peripheri
kshv
rtc
form
multipl
nuclear
foci
earli
lytic
replic
format
rtc
coincid
time
appear
nuclear
chaperon
foci
similar
virusinducedchaperoneenrich
vice
domain
form
adjac
rtc
also
observ
cell
contain
sequest
inducedvic
domain
also
accumul
ubiquitin
protein
compon
proteasom
function
sequest
misfold
protein
away
rtc
serv
protein
qualiti
control
center
redistribut
similar
seen
inducedvic
domain
observ
multipl
unreactiv
total
rna
protein
extract
sampl
despit
knockdown
mrna
level
signific
amount
protein
remain
sirnatr
sampl
b
despit
small
knockdown
protein
level
cell
signific
decreas
amount
multipl
viral
transcript
variou
tempor
class
quantifi
rtpcr
analysi
c
viral
dna
replic
assess
qpcr
follow
cell
reactiv
h
four
day
postsirna
transfect
signific
differ
observ
scrambl
cell
similar
virion
product
detect
scrambl
cell
cell
reactiv
h
four
day
postsirna
transfect
cultur
medium
centrifug
immedi
incub
cell
h
total
rna
isol
qrtpcr
carri
e
incomplet
protein
level
observ
western
blot
even
seven
day
postsirna
transfect
cell
demonstr
remark
stabil
cell
line
f
averag
three
independ
transfect
shown
error
bar
standard
deviat
ce
isoform
essenti
kshv
lytic
replic
fig
major
kshv
lytic
gene
express
unaffect
follow
specif
deplet
cell
cell
transfect
twice
nm
sirna
nm
scrambl
sirna
follow
four
day
postsirna
transfect
cell
either
reactiv
cell
undergo
kshv
lytic
replic
moreov
label
also
observ
cell
remain
posit
exclus
adjac
rtc
howev
contrast
chaperon
dynam
kshv
lytic
replic
surprisingli
larg
chaperon
foci
recruit
within
kshv
rtc
viral
dna
activ
synthesis
fig
fig
therefor
result
strongli
suggest
chaperon
may
also
aid
replic
kshv
genom
lytic
replic
therefor
suggest
isoform
may
import
role
assembl
activ
preiniti
complex
origin
dna
replic
support
observ
prokaryot
plasmid
eukaryot
saccharomyc
cerevisia
human
bacteriophag
interestingli
isoform
also
identifi
kshv
virion
therefor
addit
role
chaperon
kshv
capsid
assembl
may
also
possibl
cancer
cell
greatli
reli
member
chaperon
famili
growth
surviv
consequ
signific
effort
invest
design
small
molecul
inhibitor
specif
atpas
novel
anticanc
therapeut
success
achiev
famili
sever
inhibitor
undergo
phase
iii
clinic
trial
although
clinic
efficaci
inhibitor
somewhat
limit
inevit
upregul
inhibit
develop
inhibitor
substanti
lag
behind
inhibitor
due
lack
natur
product
inhibitor
specif
isoform
due
highli
polar
natur
atp
bind
site
high
affin
atp
display
atpas
nevertheless
recent
year
sever
inhibitor
design
test
preclin
clinic
trial
howev
major
challeng
remain
find
inhibitor
specif
discrimin
date
peptid
aptam
target
select
specif
isoform
also
recent
methyl
blue
report
specif
inhibit
oxid
cystein
atpas
domain
residu
absent
allow
differenti
target
isoform
specif
redistribut
kshv
rtc
lytic
replic
made
use
recent
develop
small
molecul
inhibitor
target
atpas
pocket
main
three
human
isoform
inhibitor
use
noncytotox
concentr
abl
effect
abrog
earli
late
kshv
transcript
togeth
viral
protein
product
viral
dna
replic
viral
progeni
therefor
studi
highlight
potenti
novel
inhibitor
prevent
kshv
lytic
replic
kshvassoci
tumour
one
could
expect
inhibit
would
directli
detriment
cancer
cell
surviv
also
virusspecif
function
depend
isoform
result
may
excit
implic
combin
recent
demonstr
efficaci
atpcompetit
inhibitor
block
kshv
latent
cycl
vitro
xenograft
kshv
tumour
model
may
case
combin
inhibitor
inhibitor
may
lead
enhanc
efficaci
erad
latent
kshv
reservoir
excitingli
cell
cultur
model
abrog
lytic
replic
without
sever
affect
cell
viabil
trigger
apoptosi
intrigu
inhibit
constitut
express
chaperon
result
cell
death
howev
import
highlight
previou
studi
carri
suscept
tumour
cell
versu
normal
cell
inhibitor
tumour
cell
h
remain
unreactiv
total
rna
protein
extract
sampl
effici
knockdown
achiev
mrna
level
protein
level
b
small
decreas
amount
gl
pan
transcript
observ
cell
c
averag
three
independ
transfect
shown
error
bar
standard
deviat
present
entir
multichaperon
complex
high
atpas
activ
contrast
normal
cell
uncomplex
conform
two
distinct
present
result
tumour
exhibit
higher
bind
affin
inhibitor
normal
thu
tempt
specul
multichaperon
foci
recruit
kshv
rtc
lytic
replic
fig
fig
sensit
chaperon
assembl
vice
domain
carri
housekeep
function
cell
surviv
would
explain
inhibit
profound
effect
kshv
lytic
replic
without
affect
cell
viabil
support
idea
isoform
specif
may
requir
treatment
kshvassoci
tumour
establish
essenti
role
isoform
kshv
lytic
replic
examin
sever
possibl
function
could
hypothesis
isoform
could
implic
stabil
essenti
viral
protein
clear
stall
rnapii
time
robust
viral
transcript
activ
viral
promot
format
kshv
rtc
initi
hypothesis
isoform
may
necessari
maintain
stabil
key
kshv
viral
protein
rta
andor
deem
possibl
kshv
latenc
essenti
viral
latenc
associ
nuclear
antigen
lana
protein
recent
shown
client
protein
chaperon
sever
inhibitor
reduc
express
lana
addit
lytic
kshv
glycoprotein
also
report
client
protein
howev
inhibit
isoform
alter
halflif
rta
fig
altern
observ
peripheri
rtc
also
believ
aid
clear
stall
rnapii
viral
genom
time
activ
transcript
inde
phosphoryl
form
rnapii
undergo
ubiquitin
robust
proteasom
degrad
infect
contrast
kshvreactiv
cell
slight
reduct
phosphoryl
rnapii
comparison
unreactiv
cell
even
late
time
h
postreactiv
fig
signific
decreas
rnapii
form
evid
fig
suggest
although
robust
rnapii
degrad
featur
observ
viru
infect
influenza
viru
may
univers
conserv
interest
note
express
dominantneg
hydrolyz
atp
infect
result
prevent
rnapii
degrad
rtc
format
howev
inhibit
isoform
prevent
slight
degrad
rnapii
protein
fig
use
transient
transfect
also
demonstr
isoform
directli
involv
activ
viral
promot
fig
strikingli
howev
inhibit
isoform
preclud
kshv
rtc
format
fig
rnapii
reloc
viral
promot
fig
thu
block
kshv
rtc
format
led
abolish
global
viral
transcript
subsequ
protein
synthesi
viral
dna
replic
result
taken
togeth
differenti
label
seen
kshvinfect
cell
suggest
chaperon
may
play
addit
role
particip
viral
dna
replic
andor
capsid
assembl
kshv
lytic
infect
compar
infect
importantli
virus
kshv
inhibit
atpas
function
lead
clear
impedi
rtc
format
present
novel
antivir
target
multipl
herpesvirus
moreov
kshv
belong
differ
subfamili
herpesvirida
famili
subfamili
respect
key
role
isoform
rtc
format
may
conserv
across
subfamili
support
notion
fact
also
report
incorpor
virion
hcmv
ebv
result
also
support
find
chaperon
kshv
virion
decad
ago
casual
chaperon
essenti
kshv
rtc
format
lytic
replic
also
detect
virion
support
conserv
role
isoform
herpesviru
infect
recent
studi
show
cellular
deplet
protein
significantli
reduc
viral
output
cell
cultur
without
advers
affect
cell
viabil
deplet
virion
also
significantli
reduc
viral
product
isoform
may
recruit
rtc
sever
reason
firstli
chaperon
may
sequest
misfold
modifi
unwant
protein
away
rtc
altern
could
produc
site
protein
remodel
andor
degrad
may
regul
delay
cellular
pathway
apoptosi
cascad
final
may
aid
subtleti
clear
stall
rnapii
complex
robust
viral
transcript
replic
addit
question
yet
address
mechan
isoform
recruit
rtc
one
intrigu
possibl
observ
made
infect
shown
interact
requir
nuclear
foci
format
interest
determin
function
kshv
homologu
also
interact
whether
nucleocytoplasm
shuttl
abil
essenti
nuclear
import
summari
identifi
new
essenti
role
isoform
format
rtc
kshv
lytic
replic
importantli
result
suggest
inhibitor
potenti
novel
kshv
antivir
agent
would
interest
test
conjunct
molecular
chaperon
inhibitor
specif
inhibitor
potenti
erad
latent
kshv
reservoir
vitro
vivo
tumour
model
cell
kindli
provid
dr
jae
jung
univers
southern
california
primari
effus
lymphoma
pel
b
cell
line
engin
induc
express
exogen
myctag
rta
addit
doxycyclin
lead
robust
reactiv
full
kshv
lytic
cycl
cell
line
kindli
provid
dr
jefferi
vieira
univers
washington
seattl
usa
maintain
kshv
latent
infect
gener
infect
cell
atcc
recombin
kshv
contain
constitut
activ
puromycin
resist
gfp
gene
rfp
gene
fuse
rtarespons
lytic
cycl
pan
promot
henc
express
rfp
use
report
rta
activ
cell
grown
dmem
life
technolog
supplement
foetal
calf
serum
fc
life
technolog
penicillinstreptomycin
ps
cell
line
kept
puromycin
sigma
select
reactiv
lytic
cycl
achiev
addit
tpa
ngml
sodium
nbutyr
nab
sigma
mm
trex
cell
line
grown
rpmi
medium
life
technolog
supplement
fc
ps
cell
line
kept
hygromycin
b
life
technolog
select
induct
perform
use
doxycyclin
hyclat
sigma
previous
describ
cell
maintain
humidifi
incub
co
plasmid
transfect
carri
use
lipofectamin
life
technolog
previous
describ
luciferas
assay
plasmid
renilla
luciferas
vector
prltk
firefli
luciferas
vector
purchas
promega
obtain
clontech
prtaegfp
ppanwt
previous
describ
monoclon
mous
antibodi
antinuclear
pore
complex
protein
gapdh
rabbit
polyclon
antilamin
rnapii
purchas
abcam
rabbit
polyclon
antihiston
cterminu
purchas
activ
motif
rabbit
polyclon
obtain
bethyl
laboratori
monoclon
antibodi
kshv
obtain
santa
cruz
mous
monoclon
enzo
life
scienc
rabbit
polyclon
purchas
cell
signal
mous
monoclon
antirnapii
purchas
millipor
mous
monoclon
anticmyc
sigma
sheep
antikshv
minor
capsid
protein
purchas
exalpha
biolog
inc
rabbit
polyclon
antirta
gift
professor
david
blackbourn
univers
surrey
uk
mous
monoclon
antigfp
suppli
clontech
inhibitor
isoform
obtain
tocri
bioscienc
silac
cell
fed
either
medium
light
label
medium
dunde
cell
product
contain
dialys
fc
dunde
cell
product
six
passag
allow
incorpor
isotop
previous
describ
subsequ
induc
lytic
replic
three
flask
reactiv
tpa
ngml
nab
h
anoth
three
flask
remain
unreactiv
control
isol
ne
protocol
publish
korfali
et
al
use
minor
modif
million
cell
use
per
experiment
condit
cell
wash
pb
incub
hypoton
lysi
buffer
mm
hepe
ph
mm
mgcl
mm
kcl
min
follow
homogen
tight
dounc
homogen
stabilis
avoid
lyse
nuclei
hypoton
swell
step
cell
resuspend
shkm
sucros
mm
hepe
ph
mm
kcl
mm
mgcl
kcl
resuspend
cell
underlay
shkm
sucros
mm
hepe
ph
mm
kcl
mm
mgcl
nuclei
pellet
min
eppendorf
centrifug
r
nuclei
resuspend
shkm
underlay
shkm
transfer
ultracentrifug
tube
beckman
coulter
nuclei
centrifug
sorval
discoveri
ultracentrifug
pellet
resuspend
shkm
mm
hepe
ph
mm
kcl
mm
mgcl
treat
tritonx
shm
sucros
mm
hepe
ph
mm
mgcl
mm
ca
cl
min
centrifug
min
nuclei
treat
rnase
thermo
scientif
dnase
life
technolog
min
pellet
min
resuspend
shm
treat
rnase
dnase
min
nuclei
centrifug
min
resuspend
incub
min
shm
contain
nacl
remov
nucleoplasm
content
nuclear
envelop
pellet
min
insolubl
nuclear
envelop
protein
solubilis
min
pb
supplement
urea
sampl
centrifug
g
min
remov
insolubl
materi
supernat
contain
nuclear
envelop
protein
store
western
blot
mass
spectrometri
analysi
solut
freshli
ad
complet
edtafre
proteas
inhibitor
roch
dtt
mm
also
freshli
ad
solut
specifi
korfali
protocol
lcmsm
perform
previous
describ
bioinformat
analysi
perform
ingenu
system
softwar
packet
ipa
ingenu
system
inc
protein
sampl
extract
use
lysi
buffer
contain
mm
tri
ph
mm
nacl
complet
edtafre
proteas
inhibitor
roch
min
ice
previous
describ
protein
sampl
run
sdspage
gel
transfer
nitrocellulos
membran
amersham
via
wet
transfer
membran
block
tb
tween
dri
skim
milk
powder
membran
probe
relev
primari
secondari
antibodi
treat
ezecl
geneflow
expos
amersham
hyperfilm
ecl
ge
healthcar
secondari
antibodi
horseradish
peroxidas
hrp
conjug
polyclon
goat
antimous
polyclon
goat
antirabbit
dako
hrpconjug
polyclon
rabbit
antisheep
santa
cruz
gfptrap
chromotek
experi
perform
previous
describ
nuclearcytoplasm
fraction
perform
previous
describ
except
nuclear
pellet
solubilis
min
pb
supplement
urea
vigor
pipet
vortex
appli
nuclear
pellet
urea
treatment
insolubl
materi
remov
centrifug
g
min
supernat
kept
analysi
cell
cultur
overnight
polyllysin
life
technolog
coat
glass
coverslip
plate
cell
fix
formaldehyd
calbiochem
min
permeabilis
triton
min
previous
describ
label
antibodi
cell
fix
icecold
methanol
five
min
permeabil
cell
incub
block
solut
pb
bsa
h
primari
antibodi
dilut
antirnapii
rabbit
rta
incub
h
coverslip
wash
five
time
pb
incub
appropri
secondari
antibodi
h
wash
five
time
pb
mount
vectashield
dapi
vector
lab
imag
obtain
use
lsm
meta
confoc
microscop
carl
zeiss
process
use
zen
imag
softwar
carl
zeiss
previous
describ
fluorescentlyconjug
secondari
antibodi
obtain
life
technolog
alexa
flour
goat
antimous
igg
alexa
flour
goat
antimous
igg
alexa
flour
goat
antirabbit
igg
alexa
flour
donkey
antimous
igg
alexa
flour
goat
antirabbit
igg
trex
cell
label
use
clickit
edu
alexa
fluor
imag
kit
life
technolog
accord
manufactur
instruct
minor
modif
follow
cell
seed
onto
polyllysin
treat
coverslip
plate
follow
induct
incub
hour
prior
cell
fixat
edu
ad
well
min
cell
fix
min
formaldehyd
permeabilis
triton
min
edu
detect
carri
ad
clickit
reaction
cocktail
min
immunofluoresc
label
rta
perform
cell
mount
vectashield
dapi
vector
lab
total
rna
cell
extract
use
trizol
life
technolog
accord
supplier
protocol
dnafre
dna
remov
kit
ambion
use
remov
contamin
dna
rna
sampl
revers
transcript
perform
protoscript
ii
neb
oligo
dt
primer
total
rna
neg
control
reaction
perform
manner
without
revers
transcriptas
quantit
pcr
qpcr
reaction
includ
sensimix
sybr
green
master
mix
biolin
primer
templat
cdna
use
dilut
rnasefre
water
cycl
perform
rotorgen
q
machin
eppendorf
cycl
programm
min
initi
preincub
follow
cycl
sec
sec
sec
qpcr
melt
curv
analysi
perform
increment
confirm
amplif
singl
product
rel
express
compar
control
cell
calcul
use
method
previous
describ
gene
interest
housekeep
gene
gapdh
standard
curv
construct
use
pool
cdna
deriv
unreactiv
reactiv
cell
six
differ
dilut
standard
quantifi
includ
dilut
slope
standard
curv
use
calcul
amplif
effici
ae
primer
use
formula
ae
mean
cycl
threshold
c
determin
three
independ
biolog
replic
gene
interest
normalis
housekeep
gene
gapdh
calcul
subtract
unreactiv
cell
reactiv
cell
fold
chang
determin
use
ae
statist
signific
valid
student
ttest
unreactiv
trex
cell
treat
dmso
use
control
assess
viral
reactiv
reactiv
cell
expos
doxycyclin
h
total
dna
isol
use
qiaamp
dna
mini
kit
qiagen
per
manufactur
instruct
qpcr
carri
describ
ng
templat
dna
primer
specif
gene
use
quantif
gapdh
gene
use
normal
sampl
mean
cycl
threshold
c
determin
three
independ
biolog
replic
rel
level
viral
dna
compar
unreactiv
cell
calcul
use
method
previous
describ
trex
cell
seed
plate
reactiv
treat
control
dmso
unreactiv
cell
treat
dmso
use
control
evalu
viral
reactiv
h
reactiv
rpmi
cultur
medium
centrifug
g
five
min
immedi
mix
dmem
supplement
fc
ps
incub
h
cell
seed
plate
previou
day
total
rna
extract
trizol
life
technolog
qrtpcr
carri
describ
rel
express
compar
control
cell
calcul
use
method
previous
describ
determin
cellular
metabol
activ
perform
use
nonradioact
celltit
aq
ueou
one
solut
cell
prolifer
assay
mt
promega
accord
manufactur
manual
cell
trex
cell
seed
triplic
flat
cultur
plate
corn
h
inhibitor
exposur
celltit
aqueou
one
solut
reagent
ad
cell
incub
h
humidifi
incub
co
absorb
measur
nm
use
infinit
tecan
plate
reader
background
control
cultur
medium
without
cell
signal
subtract
absorb
valu
assay
allow
evalu
viabil
cytotox
effector
caspas
activ
within
singl
assay
well
assay
carri
specifi
supplier
manual
trex
cell
cell
seed
triplic
tissu
cultur
treat
black
micropl
greiner
bioon
nocel
control
background
contain
cultur
medium
signal
subtract
absorb
luminesc
valu
fluoresc
luminesc
read
collect
use
glomax
system
promega
kindli
provid
dr
john
boyl
univers
leed
uk
luciferas
activ
detect
use
dualluciferas
report
assay
system
promega
previous
describ
cell
seed
triplic
flat
cultur
plate
corn
densiti
cell
per
well
follow
respect
plasmid
transfect
inhibitor
exposur
media
remov
cultur
well
cell
wash
gentli
pb
passiv
lysi
buffer
ad
cell
monolay
rock
min
lysat
transfer
tissu
cultur
treat
white
micropl
greiner
bioon
luciferas
measur
carri
fluostar
optima
micropl
reader
bmg
labtech
ltd
injector
use
dispens
luciferas
assay
reagent
ii
stop
glo
reagent
respect
firefli
luciferas
activ
normal
renilla
luciferas
activ
formaldehydecrosslink
chromatin
prepar
use
pierc
chromatin
prep
modul
thermo
scientif
follow
manufactur
protocol
x
cell
use
per
experiment
sampl
digest
six
unit
micrococc
nucleas
mnase
per
mnase
digest
buffer
water
bath
min
condit
result
optim
shear
chromatin
chromatin
fragment
rang
base
pair
immunoprecipit
carri
use
ezchip
kit
millipor
accord
supplier
instruct
previous
describ
immunoprecipit
done
overnight
contain
digest
chromatin
x
cell
chip
dilut
buffer
rnapii
antibodi
clone
millipor
isotyp
antibodi
normal
mous
igg
millipor
antibodi
provid
ezchip
kit
prior
qpcr
analysi
elut
dna
subject
dna
clean
step
use
ultraclean
pcr
cleanup
kit
mo
bio
laboratori
accord
suppli
protocol
except
use
spinclean
buffer
instead
qpcr
reaction
perform
describ
use
either
chipe
dna
input
dna
templat
sirna
knockdown
cell
seed
plate
revers
transfect
either
nm
specif
silenc
select
sirna
life
technolog
nm
allstar
neg
control
sirna
qiagen
use
siport
neofx
transfect
agent
life
technolog
per
transfect
sirna
id
respect
sirna
target
two
major
protein
two
day
posttransfect
cell
transfect
manner
four
day
first
transfect
cell
reactiv
incub
desir
time
protein
total
rna
isol
trizol
life
technolog
subsequ
western
blot
qrtpcr
perform
trex
cell
transfect
nucleofector
solut
v
lonza
sirna
scrambl
ad
addit
monitor
transfect
effici
control
plasmid
pmaxgfp
also
cotransfect
cell
transfect
use
program
amaxa
nucleofector
lonza
nucleofect
cell
maintain
sixwel
plate
medium
freshli
replac
everi
day
confoc
imag
subject
profil
analysi
use
zeiss
zen
softwar
involv
draw
line
confoc
imag
measur
rel
intens
channel
everi
pixel
along
line
profil
conduct
cell
two
repres
confoc
imag
taken
object
data
analys
use
microsoft
excel
firstli
function
use
defin
whether
rel
intens
pixel
could
defin
peak
thu
foci
function
ask
whether
data
point
one
specif
pixel
rhodamin
channel
set
arbitrari
threshold
elimin
background
nois
condit
met
function
ask
whether
data
point
greater
equal
data
point
previou
subsequ
pixel
condit
true
data
point
count
peak
perform
everi
data
point
measur
line
profil
provid
total
number
peak
profil
one
cell
next
anoth
function
use
determin
whether
rel
intens
dapi
channel
threshold
determin
visualis
line
profil
data
graph
pixel
shown
exceed
threshold
dapi
channel
also
rhodamin
channel
count
nuclear
peak
measur
conduct
pixel
profil
allow
count
nuclear
peak
profil
peak
outsid
nucleu
correspond
cytoplasm
peak
oligonucleotid
primer
sequenc
avail
upon
request
primer
purchas
sigma
uk
support
inform
tabl
cellular
protein
previous
report
localis
herpesviru
rtc
found
significantli
increas
ne
reactiv
cell
xl
fig
redistribut
cytoplasm
peripheri
within
kshvinduc
rtc
trex
cell
remain
unreactiv
reactiv
either
h
h
unreactiv
cell
cytoplasm
contrast
h
reactiv
increas
nuclear
label
seen
numer
small
foci
found
mainli
adjac
viral
rtc
ii
cell
display
complet
recruit
within
rtc
iii
iv
asterisk
cell
accumul
larg
adjac
rtc
iv
arrow
b
trex
cell
remain
unreactiv
reactiv
h
ii
iii
follow
triplelabel
antibodi
specif
rta
clickit
edu
alexa
fluor
complet
colocalis
rta
activ
replic
viral
dna
edulabel
observ
incipi
rtc
ii
fullydevelop
rtc
iii
note
cell
deplet
cytoplasm
trex
cell
remain
unreactiv
reactiv
h
presenc
control
dmso
follow
label
clickit
edu
alexa
fluor
antibodi
specif
rnapii
clone
high
proport
unreactiv
trex
cell
replic
cellular
dna
edulabel
presenc
control
dmso
normal
rnapii
local
observ
cell
nuclear
rnapii
exclud
nucleoli
b
contrast
reactiv
cell
enter
cell
cycl
arrest
demonstr
fewer
edulabel
cell
presenc
dmso
multipl
rtc
form
replic
viral
dna
white
arrow
cell
treat
multipl
prerepl
site
seen
label
rnapii
antibodi
edulabel
diffus
nucleu
compar
dmsotreat
cell
tif
